Compare Becton Dickinson and Co (BDX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs TG Therapeutics Inc — how do they compare? Becton Dickinson and Co trades at $151.5 (market cap $41.51B), while TG Therapeutics Inc trades at $54.47 (market cap $8.41B). The key difference: Becton Dickinson and Co is far larger — about 4.9× TG Therapeutics Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BDX | TGTX | |
|---|---|---|
Market Cap | $41.51B | $8.41B |
Sector | Health | Health |
52-Week High | $185.39 | $59.06 |
52-Week Low | $135.49 | $26.39 |
Enterprise Value | $57.97B | $8.65B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $55.01, down 3.69% today, with a bullish technical signal from moving averages and a consensus analyst rating of 'Buy' from 11 of 13 analysts. The company reported strong revenue growth to $616.29 million in 2025 and a net income of $447.18 million, though recent quarterly EPS misses and negative operating cash flow of -$24.77 million highlight volatility. Positive news includes Phase II trials for Briumvi in schizophrenia and Phase I success in myasthenia gravis, driving investor optimism.
Outlook: TGTX offers growth potential through pipeline expansion and robust sales guidance, but faces risks from clinical trial outcomes, cash flow challenges, and high valuation multiples. The stock's 70% year-to-date gain reflects high expectations, requiring careful monitoring of execution against earnings forecasts and regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
